Christina A. Reith

Learn More
BACKGROUND Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of(More)
BACKGROUND Statin therapy reduces the risk of occlusive vascular events, but uncertainty remains about potential effects on cancer. We sought to provide a detailed assessment of any effects on cancer of lowering LDL cholesterol (LDL-C) with a statin using individual patient records from 175,000 patients in 27 large-scale statin trials. METHODS AND(More)
This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how(More)
BACKGROUND The relevance of the cause of kidney disease to prognosis among patients with chronic kidney disease is uncertain. STUDY DESIGN Observational study. SETTINGS & PARTICIPANTS 6,245 nondialysis participants in the Study of Heart and Renal Protection (SHARP). PREDICTOR Baseline cause of kidney disease was categorized into 4 groups: cystic(More)
Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but the effects of such treatment on progression of kidney disease remain uncertain. Here, 6245 participants with CKD (not on dialysis) were randomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or matching placebo. The main prespecified renal outcome was(More)
BACKGROUND The absolute and relative importance of smoking to vascular and nonvascular outcomes in people with chronic kidney disease (CKD), as well its relevance to kidney disease progression, is uncertain. STUDY DESIGN Observational study. SETTING & PARTICIPANTS 9,270 participants with CKD enrolled in SHARP. PREDICTOR Baseline smoking status(More)
PURPOSE OF REVIEW To examine the current evidence concerning the effects of genetic variation on statin-related low-density lipoprotein cholesterol reductions, clinical efficacy, and adverse events and the relevance for patient care. RECENT FINDINGS Recent years have seen the emergence of large-scale genetic experiments, including genome-wide association(More)
Since their widespread introduction in the middle of the 20th century, randomized trials of sufficiently large size have provided reliable assessments of the safety and efficacy of treatments that have produced substantial improvements in health.1 During the past decade, however, increasingly onerous regulation and related bureaucracy have made trials much(More)
n engl j med 369;23 nejm.org december 5, 2013 2268 The Authors Reply: Auger and Jamieson highlight the importance of pulmonary endarterectomy as a potentially curative treatment for chronic thromboembolic pulmonary hypertension. In CHEST-1, rigorous measures were taken to ensure that only patients with chronic thromboembolic pulmonary hypertension that was(More)